Recently published article hoping to get clues. I've asked for a reprint. Her Harvard presentation in July should give us insights on her clinical experience.
"Safe and effective". Physicians, especially someone like DePinho, will never use these terms without scientific proof.
Let's not forget, he did not have to mention it. Plus, if he thought Neuvax was ineffective, he would have stayed away from that comment.
Don't bother answering my posts, idiot and worthless. You must have a proud daddy and mommy.
"This safe and effective vaccine, HER2 vaccine, appears to eliminate the recurrence of the disease in the vast majority of those patients that would otherwise recur."
Check out his Bio....
Definately! He's from MD Anderson. He knows more than you and I.....these docs. chat, rounds, grandrounds,inter-dept meetings, etc....quite an important statement
In addition, we have also for diseases that have been treated like HER2 breast cancer, a certain form of breast cancer, Elizabeth Mittendorf here, at MD Anderson, developed a HER2 vaccine. About a quarter of patients will recur with the disease and ultimately succumb to the disease after standard treatment with Herceptin. This safe and effective vaccine, HER2 vaccine, appears to eliminate the recurrence of the disease in the vast majority of those patients that would otherwise recur. So those are some examples, other than a treatment of advanced disease, how we can harness the power of the immune system, both at the front end and at the back end of treatment.
The diane rehm show.... - The/2016-04-21. New-promise-for-immunotherapy-cancer-drugs
See transcript at 10:44.....this is quite a statement.....
Interesting. Two things: a) I suspect the 70th event was end of February, rather than March - the adjudication committee confirmed in March (usually takes a few weeks getting those things organized and reviewed) b)I think recurrence rates should be at 18%, conservative, but most likely. If you bring these changes, what's the output?
I have a feeling that this will also be part of the interim analysis. This is key data likely addressing prospectively what patient type will benefit from Neuvax. This is called targeted therapy at its best. This is the type of surrogate marker analysis I was referring to in another one of my post a few weeks ago.
Whiskey - it's an article that will get us some good traction and visibility. ASCO abstract/presentation is another thing. We will know sometime in May, I believe.
I'm glad she's getting the attention. She's a super key early adopter physician --- all pharmas would love to have her on their side.
from the ASCO POST, April 2016. Who would you believe? Fartstein? Trolls herein? Or Dr. E. Mittendorf?
Encouraging results are coming in for her groups’ E75 HER2-derived peptide vaccine, nelipepimut-S (NeuVax), in early-stage breast cancer patients. E75
Rule, supremacy, prediction. He uses those three words. He is such a loser. His stupid, non-sense rule. That and flipping a coin is the same. He's such an idiot.
Accelerated approval is given to drugs based on a surrogate endpoint such as a radiographic image or laboratory measure that points to a clinical benefit.
Surrogate endpoints are used when clinical trials may require too many patients and the outcome may take too long. Companies are required to conduct studies to confirm the anticipated benefit. If a confirmatory trial does not prove such a benefit, the FDA can revoke the approval.
Cocky for someone that comes from Flatrock NFLD. Cocky canadian.